PDF(Pubmed)
Abstract：
UNASSIGNED: We search the current literature on data regarding the role of RT in OM treatment, focusing on the improvement of symptoms and patient quality of life.
UNASSIGNED: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations.
UNASSIGNED: From 340 citations, 60 papers were finally selected: 45 case reports and 15 case series. The case reports accounted for 47 patients. In 37/39 cases (95%), EBRT was done. Patients were mainly treated with 3DCRT, IMRT, and with SBRT. The most used RT regimens were 30 Gy in 10 fractions (23%) and 20-25 Gy in 5 fx (13%). No sever toxicity was reported. A median LC of 11 months (range 1-54 months) and a median OS of 12 months (range 1-54 months) were registered. Among the case series, a total of 457 patients were examined, 227 of whom underwent RT. The main used techniques were 3DCRT, CK, GK, SBRT, and BRT. RT doses could vary from 30 Gy/10 fractions to 60 Gy/30 fractions, 50 Gy/5 fractions, or 16.5-21 Gy in single fraction. No toxicity above G2 was reported. ORR could vary between 75 and 100%. Only two study provided information on response duration: a mean LC time of 22.8 months and a mean time to local progression of 5 months (range: 3-7). Regarding OS, the data were heterogeneous, ranging between 1 and 54 months.
UNASSIGNED: RT for OM seems to be a safe and feasible option. More information on the RT ideal techniques and dose are still needed.
UNASSIGNED: This paper tried to sum up the few and fragmented data on the use of radiotherapy for orbital metastases: the possible option ranged from 3D- and 2D-CRT to SBRT, CK, and GK, with different possible fractionations (30Gy in 10 fractions, 60 Gy/30 fractions, 20-50 Gy/5 fractions, or 16.5-21 Gy in single fraction). Regardless of the chosen approach, almost all treated patients experienced a benefit after RT in terms of OM-related symptom intensity reduction and a good acute and late toxicity profile.
UNASSIGNED: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations.
UNASSIGNED: From 340 citations, 60 papers were finally selected: 45 case reports and 15 case series. The case reports accounted for 47 patients. In 37/39 cases (95%), EBRT was done. Patients were mainly treated with 3DCRT, IMRT, and with SBRT. The most used RT regimens were 30 Gy in 10 fractions (23%) and 20-25 Gy in 5 fx (13%). No sever toxicity was reported. A median LC of 11 months (range 1-54 months) and a median OS of 12 months (range 1-54 months) were registered. Among the case series, a total of 457 patients were examined, 227 of whom underwent RT. The main used techniques were 3DCRT, CK, GK, SBRT, and BRT. RT doses could vary from 30 Gy/10 fractions to 60 Gy/30 fractions, 50 Gy/5 fractions, or 16.5-21 Gy in single fraction. No toxicity above G2 was reported. ORR could vary between 75 and 100%. Only two study provided information on response duration: a mean LC time of 22.8 months and a mean time to local progression of 5 months (range: 3-7). Regarding OS, the data were heterogeneous, ranging between 1 and 54 months.
UNASSIGNED: RT for OM seems to be a safe and feasible option. More information on the RT ideal techniques and dose are still needed.
UNASSIGNED: This paper tried to sum up the few and fragmented data on the use of radiotherapy for orbital metastases: the possible option ranged from 3D- and 2D-CRT to SBRT, CK, and GK, with different possible fractionations (30Gy in 10 fractions, 60 Gy/30 fractions, 20-50 Gy/5 fractions, or 16.5-21 Gy in single fraction). Regardless of the chosen approach, almost all treated patients experienced a benefit after RT in terms of OM-related symptom intensity reduction and a good acute and late toxicity profile.
摘要：
■我们搜索有关RT在OM治疗中的作用的现有文献，专注于改善症状和患者生活质量。
■本系统评价遵循系统评价和荟萃分析（PRISMA）建议的首选报告项目。
■来自340次引用，最终选择60篇论文：45例病例报告和15例病例系列。病例报告占47例。在37/39例（95％）中，进行了EBRT。患者以3DCRT为主,IMRT,和SBRT。最常用的RT方案是10分（23％）的30Gy和5fx（13％）的20-25Gy。没有报道严重的毒性。登记的中位LC为11个月(范围1-54个月)和中位OS为12个月(范围1-54个月)。在案件系列中，总共检查了457名患者，其中227人接受了RT。主要使用的技术是3DCRT，CK,GK,SBRT,和BRT。RT剂量可以从30Gy/10分数到60Gy/30分数不等，50Gy/5分数，或16.5-21Gy的单一部分。没有报道超过G2的毒性。ORR可以在75%和100%之间变化。只有两项研究提供了有关反应持续时间的信息：平均LC时间为22.8个月，平均局部进展时间为5个月（范围：3-7）。关于OS,数据是异构的，1到54个月不等。
■用于OM的RT似乎是一个安全可行的选择。仍然需要有关RT理想技术和剂量的更多信息。
■本文试图总结关于使用放射疗法治疗眼眶转移的少数零碎数据：可能的选择范围从3D和2D-CRT到SBRT，CK,GK,具有不同的可能分馏(10个馏分中的30Gy，60Gy/30分，20-50Gy/5分，或16.5-21Gy的单个部分)。不管选择哪种方法,几乎所有接受治疗的患者在RT后都在OM相关症状强度降低以及良好的急性和晚期毒性方面获益.
■本系统评价遵循系统评价和荟萃分析（PRISMA）建议的首选报告项目。
■来自340次引用，最终选择60篇论文：45例病例报告和15例病例系列。病例报告占47例。在37/39例（95％）中，进行了EBRT。患者以3DCRT为主,IMRT,和SBRT。最常用的RT方案是10分（23％）的30Gy和5fx（13％）的20-25Gy。没有报道严重的毒性。登记的中位LC为11个月(范围1-54个月)和中位OS为12个月(范围1-54个月)。在案件系列中，总共检查了457名患者，其中227人接受了RT。主要使用的技术是3DCRT，CK,GK,SBRT,和BRT。RT剂量可以从30Gy/10分数到60Gy/30分数不等，50Gy/5分数，或16.5-21Gy的单一部分。没有报道超过G2的毒性。ORR可以在75%和100%之间变化。只有两项研究提供了有关反应持续时间的信息：平均LC时间为22.8个月，平均局部进展时间为5个月（范围：3-7）。关于OS,数据是异构的，1到54个月不等。
■用于OM的RT似乎是一个安全可行的选择。仍然需要有关RT理想技术和剂量的更多信息。
■本文试图总结关于使用放射疗法治疗眼眶转移的少数零碎数据：可能的选择范围从3D和2D-CRT到SBRT，CK,GK,具有不同的可能分馏(10个馏分中的30Gy，60Gy/30分，20-50Gy/5分，或16.5-21Gy的单个部分)。不管选择哪种方法,几乎所有接受治疗的患者在RT后都在OM相关症状强度降低以及良好的急性和晚期毒性方面获益.
